[Retracted] Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C

Table 1

Efficacy evaluation criteria.

Efficacy indicators	Specific information
Complete response	HBeAg and HBV-DNA turned negative, anti-HBe showed positive, and ALT returned to normal.
Partial response	HBeAg and HBV-DNA turned negative, but anti-HBe showed negative and ALT returned to normal.
No response	HBeAg and HBV-DNA remained positive, anti-HBe was negative, and ALT remained abnormal.
Sustained response	Patients with complete or partial response had sustained response within 6 to 12 months after discontinuation.
Recurrence	Patients with complete or partial response developed ALT abnormalities or HBV-DNA turned positive within 6 to 12 months after discontinuation.